The Latest Breaking News on Pharma

Myricx Bio’s £90 million Series A fundraising will initially focus on developing its work treating solid tumours, such as breast and gastric cancers, but potentially can apply across all cancers

The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…

The Supreme Court has rejected a settlement for OxyContin maker Purdue Pharma and members of the Sackler family who own the company

The Supreme Court said the Sackler family cannot use a Chapter 11 reorganization plan to protect themselves from civil liability

Controversial deal would have protected billionaire family owners from further liability over US opioid epidemic

Walgreens is finalizing a plan to fix its business that could result in the closure of hundreds of additional stores in the next three years

The Supreme Court has rejected a nationwide settlement with OxyContin maker Purdue Pharma that would've shielded Sackler family members who own the company from civil lawsuits over the toll of opioids but also would've provided billions of dollars to combat the epidemic

Pharmaceutical and cosmetic companies are the number one consumers of this tech, but other industries are taking notice.

Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product Wegovy